Jubilant Pharmova Limited has informed the Exchange regarding Resignation of Mr Mr. Arvind Chokhany, Whole-time Director & CFO as Chief Financial Officer of the company w.e.f. July 29, 2025.
JUBLPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 3.2 pts less than Nifty Smallcap 250 and 3.1 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Mr. Arvind Chokhany has resigned from his position as Chief Financial Officer and Whole-time Director of Jubilant Pharmova Limited. While his resignation letter is dated July 29, 2025, he will continue to hold office until the close of business hours on September 30, 2025, ensuring a roughly two-month transition period. As per his resignation letter, he is leaving to take up an external opportunity. The company has not yet disclosed who will replace him.
The departure of the CFO and WTD is a notable leadership change that may create short-term uncertainty, though the orderly handover period until end-September reduces immediate disruption. Investors should track the announcement of a new CFO, as financial leadership continuity is important for execution of strategy and reporting.